Cortex District Member C2N Diagnostics Receives $10M Investment from Samsung

A St. Louis-based company known for its work in Alzheimer's and neurological testing can expand its footprint, thanks to a $10 million investment from several life sciences companies under South Korean company Samsung.

C2N Diagnostics LLC said that Samsung C&T Corp., Samsung Biologics, Samsung Bioepis and Samsung Venture Investment Corp. all contributed to the $10 million investment.

The arm of Samsung focused on life sciences has "contributed to the stabilization of the biopharmaceutical supply chain" and made high quality pharmaceuticals easier to access, Jaywoo Kim, executive vice president of Samsung C&T Corp., said Thursday in a press release.